Nephros Inc. (NEPH) Dividend History

Nephros Inc. is a medical device company specializing in water and air filtration solutions for healthcare and environmental applications. The company develops and markets advanced filtration systems designed to improve water safety in hospitals, dialysis centers, and other medical settings, as well as air purification products aimed at enhancing air quality. Founded in the early 2000s, Nephros focuses on providing reliable filtration technologies to address infection control and safety concerns in clinical and environmental environments.

380 Lackawanna Place, South Orange, NJ, 07079
Phone: 201.343.5202
Website:

Dividend History

Nephros Inc. currently does not pay dividends

Company News

  • Full-Year Net Revenue of $14.2 Million and Fourth-Quarter Net Revenue of $3.3 Million

    GlobeNewswire Inc.
  • SOUTH ORANGE, NJ, Feb. 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will file its fourth quarter and fiscal year financial results on Thursday March 7, 2024 after market close and will host a conference call that same day at 4:30pm ET.

    GlobeNewswire Inc.
  • Shares of Despegar.com, Corp. (NYSE: DESP) rose sharply during Wednesday’s session after the company raised its FY23 financial guidance. The company said it now sees revenue of $690 million to $700 million, versus previous forecast of $670 million to $700 million. Despegar.com shares gained 16.4% to $9.90 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers Shattuck Labs, Inc. (NASDAQ: STTK) jumped 127.5% to $4.80 after the company announced initial topline dose-expansion data from its ongoing Phase 1A/B clinical trial of SL-172154 in combination with AZA in frontline HR-MDS and TP53m AML patients. ReShape Lifesciences Inc. (NASDAQ: RSLS) shares gained 63.8% to $0.4110 after the company announced it received FDA PMA supplement approval for its next-generation Lap-Band 2.0 FLEX. C4 Therapeutics, Inc. (NASDAQ: CCCC) shares jumped 59% to $3.7199 after the company announced data from the CFT7455 Phase 1 trial in relapsed/refractory multiple myeloma. Following the update, Stifel analyst Bradley Canino upgraded C4 Therapeutics from Hold to Buy and raised the price target from $2 to $12. RiskOn International, Inc. (NASDAQ: ROI) shares gained 38.3% to $0.2016 after declining 9% on Tuesday. Innovative International Acquisition Corp. (NASDAQ: IOAC) shares rose 36% to $11.66. NextPlay Technologies, Inc. (NASDAQ: NXTP) shares gained 26% to $1.1708 after surging 29% on Tuesday. Nephros, Inc. (NASDAQ: NEPH) rose 23% to $3.16. SciSparc Ltd. (NASDAQ: SPRC) gained 21.7% to $5.95 after the company announced results for MitoCareX Bio with its drug discovery platform. Eos Energy Enterprises, ...

    Benzinga
  • The Dow Jones index closed higher by over 150 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Nephros The Trade: Nephros, Inc. (NASDAQ: NEPH) Director, President and CEO Robert R. Banks Jr. acquired a total of 18,000 shares an average price of $2.20. To acquire these shares, it cost around $39,647. What’s Happening: On Nov. 8, Nephros posted better-than-expected quarterly results. What ...

    Benzinga
    Featured Companies: DCTH FTCI
  • Third-Quarter Net Revenue of $3.7 Million, a 55% Increase Over 2022; Net Loss from Continuing Operations Narrows 85% to $0.2 Million; $1.1 Million in Positive Year-to-Date Net Cash Flows from Operating Activities

    GlobeNewswire Inc.
Dividend data last updated 06/06/2025 21:42:35 UTC